Abderrahim El Guerrab

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer

Abderrahim El Guerrab, Mahchid Bamdad, Fabrice Kwiatkowski et al. · Oncotarget · 2016 · 114 citations · Full text

Breast Oncology, Medicine, Immunology +15

Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells

Abderrahim El Guerrab, Mahchid Bamdad, Yves‐Jean Bignon et al. · Scientific Reports · 2020 · 67 citations · Full text

Cholinergic Neurotransmission in the Posterior Insular Cortex Is Altered in Preclinical Models of Neuropathic Pain: Key Role of Muscarinic M2 Receptors in Donepezil-Induced Antinociception

Jérémy Ferrier, Mathilde Bayet‐Robert, Romain Dalmann et al. · Journal of Neuroscience · 2015 · 62 citations · Full text

Homoharringtonine, an approved anti-leukemia drug, suppresses triple negative breast cancer growth through a rapid reduction of anti-apoptotic protein abundance.

Mohamad Yakhni, Arnaud Briat, Abderrahim El Guerrab et al. · PubMed · 2019 · 50 citations · Full text

Differential Impact of EGFR-Targeted Therapies on Hypoxia Responses: Implications for Treatment Sensitivity in Triple-Negative Metastatic Breast Cancer

Abderrahim El Guerrab, Zegrour Rabah, Carine-Christiane Nemlin et al. · PLoS ONE · 2011 · 35 citations · Full text